arrow
S

Susana R�os

AstraZeneca
H指数:25
被引数:3,720

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recurrence factors in familial papillary thyroid carcinoma

家族性乳头状甲状腺癌的复发因素

2025-12-010
PRE
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

FOXO3与FOXM1的相互作用影响PIK3CA及PIK3CA/PTEN变异的雌激素受体阳性乳腺癌对AKT抑制的敏感性。

2025-04-220
OA
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation

乳腺癌细胞的多组学分析揭示了与AKT降解相关的应激MAPK敏感性

2024-02-273
OA
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
2023-09-190
OAAI
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

下一代口服选择性雌激素受体降解剂Camizestrant (AZD9833) 抑制ER乳腺癌生长并克服内分泌和CDK4/6抑制剂抗性

2023-09-1916
OAAI
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
2023-08-180
OA
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
2023-08-0512
OAAI
The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
2023-03-012
OA
Enhanced detection of circulating tumor DNA by fragment size analysis
2018-11-07671
OAAI